Filing Details
- Accession Number:
- 0001209191-16-137315
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-08-16 18:20:55
- Reporting Period:
- 2016-08-16
- Filing Date:
- 2016-08-16
- Accepted Time:
- 2016-08-16 18:20:55
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1377121 | Protagonist Therapeutics Inc | PTGX | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1656151 | Armen Shanafelt | C/O Lilly Ventures 115 West Wahington St., Suite 1680-South Indianapolis IN 46204 | Yes | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2016-08-16 | 206,896 | $0.00 | 206,896 | No | 4 | C | Indirect | By Fund |
Common Stock | Acquisiton | 2016-08-16 | 630,541 | $0.00 | 837,437 | No | 4 | C | Indirect | By Fund |
Common Stock | Acquisiton | 2016-08-16 | 678,712 | $0.00 | 1,516,149 | No | 4 | C | Indirect | By Fund |
Common Stock | Acquisiton | 2016-08-16 | 583,333 | $12.00 | 2,099,482 | No | 4 | P | Indirect | By Fund |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | C | Indirect | By Fund |
No | 4 | C | Indirect | By Fund |
No | 4 | C | Indirect | By Fund |
No | 4 | P | Indirect | By Fund |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Series A Preferred Stock | Disposition | 2016-08-16 | 3,000,000 | $0.00 | 206,896 | $0.00 |
Common Stock | Series B Preferred Stock | Disposition | 2016-08-16 | 9,142,857 | $0.00 | 630,541 | $0.00 |
Common Stock | Series C Preferred Stock | Disposition | 2016-08-16 | 9,841,333 | $0.00 | 678,712 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect |
Footnotes
- Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock automatically converted into the Issuer's common stock on a 1-for-14.5 basis at the closing of the Issuer's initial public offering and had no expiration date.
- These shares are held directly by Lilly Ventures Fund I, LLC (LVFI). LV Management Group, LLC (LVMG) is the management company for LVFI and has voting and dispositive power over the shares held by LVFI. As such, LVMG may be deemed to indirectly beneficially own the shares held by LVFI. LVMG's voting and dispositive decisions with respect to the shares held by LVFI are made by LVMG's management committee, which includes the reporting person. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his respective proportionate pecuniary interest therein.